Indianapolis, Indiana, United States
Accomplished biopharmaceutical executive and physician-scientist with over 30 years of experience, driving innovation across global R&D, translational medicine, and clinical development. Former Vice President and Global Head at Eli Lilly, with prior leadership roles at Takeda, Novartis, AstraZeneca, and Quintiles (now IQVIA). Expert in advancing assets from candidate selection through all clinical phases to marketing authorisation across neurology, immunology, respiratory, cardiovascular, and metabolic diseases. Renowned for building and leading high-performing, cross-functional organisations, optimising development strategies, and implementing industry-first translational platforms. Combines deep medical and scientific expertise with business acumen to accelerate development pipelines, strengthen portfolio value, and deliver differentiated therapies to patients worldwide.
Founded a successful fluid art studio in Noblesville, IN, delivering hands-on creative experiences across individual, corporate, and private events. Achieved profitability within six months, while forging community partnerships to strengthen local arts initiatives. Driving strategic marketing and engagement efforts, leveraging Chamber of Commerce networks to expand reach and brand presence.
Led translational siRNA development program in neurodegenerative diseases
Directed the global Exploratory Medicine & Clinical Pharmacology (EMP) organisation, setting strategy across major therapeutic areas and overseeing scientific, operational, and line management functions. Led the Lilly Centre for Clinical Pharmacology (Singapore), guiding Phase I strategy, clinical innovation, and cross-site capability development. Built global external networks with academic and clinical partners to strengthen translational and early-phase development capabilities. Therapeutic areas: Neuroscience Diabetes and CV Autoimmune Diseases
Led Neuroscience therapeutic area within Clinical Pharmacology organization as well as the Neuroscience Design Hub. Introduced first-in-industry master protocol platforms for evaluation of pain interventions Enhanced organizational collaboration across research, pharmacology, and analytics.
General Manager and Strategy Lead of Translational Drug Research Unit Head of Unit Executive Leadership Team Implementation and oversight of all operational processes, including: - Safety and well-being of healthy volunteers and patients - Performance of high quality translational studies - Finance, Quality Assurance and HR support functions Development and maintenance of partnerships with key customers Collaboration with and participation in business development function Leadership of initiatives in standard setting for Quality policies and procedures Integration of Unit with other company business units and Quintiles Centers of Excellence
Project leader, heading interdisciplinary teams of clinicians, pharmacists and scientists, responsible for: - Design of clinical development strategies - Planning and execution of early and late trials - Exploration of asset maximization strategy Adviser on corporate strategy in respiratory medicine Medical lead and accountability for programs in various disease areas including: - Infant Respiratory Distress Syndrome - Idiopathic Pulmonary Fibrosis - Psoriasis
Project Leader, managing a team of 12 scientists responsible for respiratory drug development projects ranging from Candidate selection to Proof-of-Concept Clinical Pharmacology expert, leading compound profiling of late-phase projects Specialty Area: Pulmonary Hypertension Submission of compound targeting Pulmonary Arterial Hypertension for Market Authorization (NDA/MAA) Organizer and moderator of 2 day workshop and advisory board meeting on novel biomarkers and technologies for use in clinical trials investigating the efficacy of drugs in Pulmonary Arterial Hypertension Member of internal respiratory biomarker group Translational Medicine Representative on 2 Global Product Teams Medical Lead and overall accountability for: Proof-of-Concept study investigating the effects of a novel compound targeting acute exacerbations in COPD ADME (mass balance) study of a novel compound targeting acute exacerbations in COPD Proof-of-Concept study investigating the effects of nilotinib in patients with Pulmonary Arterial Hypertension Proof-of-Concept extension study investigating the long-term safety and effect on 6 minute-walking distance of imatinib in patients suffering from Pulmonary Arterial Hypertension Pharmacokinetic study investigating the drug-drug interactions between imatinib, bosentan Member of ABPI Experimental Medicine Expert Network Editor of 2012 ABPI Phase 1 Guidelines